恒瑞医药：获得阿得贝利单抗注射液等5款药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of several new drugs, indicating progress in its drug development pipeline [1] Drug Development - The company and its subsidiaries have been granted clinical trial approval for the following drugs: - HRS-7058 capsules - HRS-7058 tablets - SHR-9839(sc) - Adebali monoclonal antibody injection - Bevacizumab injection - SHR-A2102 injection [1] Investment in R&D - The cumulative R&D investments for these drugs are as follows: - HRS-7058: approximately 72.31 million yuan - SHR-9839(sc): approximately 968.98 million yuan - Adebali monoclonal antibody: approximately 364.73 million yuan - Bevacizumab injection: approximately 248.22 million yuan - SHR-A2102: approximately 63.91 million yuan [1] Regulatory Process - Following the approval of clinical trial notifications, these drugs must undergo clinical trials and receive further evaluation and approval from the National Medical Products Administration before they can be manufactured and marketed [1]